The case for publicly funding lorlatinib

N Z Med J. 2024 Aug 23;137(1601):77-79. doi: 10.26635/6965.6661.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aminopyridines* / economics
  • Aminopyridines* / therapeutic use
  • Humans
  • Lactams* / economics
  • Lactams, Macrocyclic / economics
  • New Zealand
  • Pyrazoles* / economics
  • Pyrazoles* / therapeutic use

Substances

  • Lactams
  • Pyrazoles
  • lorlatinib
  • Aminopyridines
  • Lactams, Macrocyclic